Rivaroxaban ‘beneficial’ after revascularisation for claudication
Further results from the VOYAGER-PAD trial show use of the agent reduces major cardiovascular events
![senior man walking with 2 canes](https://www.ausdoc.com.au/wp-content/uploads/2022/08/senior20walk20cane20dreamstime_m_4414161-1.jpg)
Patients who undergo lower extremity revascularisation for claudication and then have rivaroxaban have fewer major cardiovascular events than if they take placebo, researchers report.
The results come from a post-hoc sub-analysis of the VOYAGER-PAD trial, looking just at data for 5031 patients who had their revascularisation procedure for claudication.